Dr Farrukh Shah
MBBS, MRCP, MRCPath, MD res
Consultant Haematologist
About
-
Biography icon plus
Dr Farrukh Shah has a specialist interest in the management of transfusional iron overload and haemoglobinopathies. She is also the current Chair of the National Haemoglobinopathy Registry and the Chair of the UK Forum on haemoglobin Disorders. She has been on the Clinical Reference Group for haemoglobinopathies since 2013 and involved in the development of the new Haemoglobinopathy commissioning model.
Dr Shah graduated from Fatima Jinnah Medical College, Lahore, Pakistan in 1994 and subsequently trained in haematology at University College London Hospitals (UCLH), completing her MD thesis titled: “The relationship between non-transferrin bound iron and iron overload in thalassaemia and sickle syndromes” under the supervision of Professor John Porter.
Dr Shah has been a consultant since 2004 and currently works at The Whittington Hospital and UCLH, and provides outreach support at the Royal Free Hospital and Luton and Dunstable Hospitals as part of the Whittington/UCLH Specialist Haemoglobinopathy team.
She is actively involved in clinical research and trials in-patients with haemoglobinopathies. She has published widely and has been actively involved in development of local and national guidelines on management of haemoglobinopathy patients and is recognised internationally as an expert in thalassaemia and haemoglobinopathies. -
Clinical interests icon plus
- Haemoglobinopathies: Thalassaemia and Sickle Cell
- Haemochromatosis and iron overload disorders
- Anaemias
-
Publications icon plus
- Shah FT, Sayani F, Trompeter S, Drasar E, Piga A. Challenges of blood transfusions in β-thalassemia. Blood Rev. 2019 Sep;37. Epub 2019 Jul 6.
- Vosper J, Evangeli M, Porter JB, Shah F. Psychological Factors Associated with Episodic Chelation Adherence in Thalassemia Hemoglobin. 2018 Jan;42(1):30-36.
- Vlachodimitropoulou E, Thomas A, Shah F, Kyei-Mensah A. Pregnancy and iron status in β-thalassaemia major and intermedia: six years' experience in a North London Hospital. J Obstet Gynaecol. 2018 May;38(4):567-570.
- Zonoozi S, Barnard M, Prescott E, Jones R, Shah FT, Tzoulis P. Effectiveness and Safety of Sitagliptin in Patients with Beta-thalassaemia Major and Diabetes Mellitus: A Case Series. Mediterr J Hematol Infect Dis. 2017 Jan 1;9(1):e2017004. doi: 10.4084/MJHID.2017.004. eCollection 2017.
- Sado DM, Maestrini V, Piechnik SK, Banypersad SM, White SK, Flett AS, Robson MD, Neubauer S, Ariti C, Arai A, Kellman P, Yamamura J, Schoennagel BP, Shah F, Davis B, Trompeter S, Walker M, Porter J, Moon JC. Noncontrast myocardial T1 mapping using cardiovascular magnetic resonance for iron overload. J Magn Reson Imaging. 2015 Jun;41(6):1505-11.
- Tzoulis P, Ang AL, Shah FT, Berovic M, Prescott E, Jones R, Barnard M. Prevalence of low bone mass and vitamin D deficiency in β-thalassemia major. Hemoglobin. 2014;38(3):173-8. Epub 2014 Apr 24.
- Pennell DJ1, Porter JB, Piga A, Lai Y, El-Beshlawy A, Belhoul KM, Elalfy M, Yesilipek A, Kilinç Y, Lawniczek T, Habr D, Weisskopf M, Zhang Y, Aydinok Y; CORDELIA study investigators. A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA). Blood. 2014 Mar 6;123(10):1447-54. doi: 10.1182/blood-2013-04-497842. Epub 2014 Jan 2
- Chatterjee R, Bajoria R, Shah FT, Porter JB, Fedele S. High index of suspicion for early diagnosis of alendronate-induced stage zero osteonecrosis of jaw in thalassaemia major. Br J Haematol. 2014 Jul;166(2):292-4. doi: 10.1111/bjh.12833. Epub 2014 Mar 14.
- Ang AL, Tzoulis P, Prescott E, Davis BA, Barnard M, Shah FT. History of myocardial iron loading is a strong risk factor for diabetes mellitus and hypogonadism in adults with β thalassemia major. Eur J Haematol. 2014 Mar;92(3):229-36.
Carpenter JP, Grasso AE, Porter JB, Shah F, Dooley J, Pennell DJ. On myocardial siderosis and left ventricular dysfunction in hemochromatosis. J Cardiovasc Magn Reson. 2013 Mar 19;15:24.
- Chatterjee R, Shah FT, Davis BA, Byers M, Sooranna D, Bajoria R, Pringle J, Porter JB. Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β-thalassaemia presenting with osteopenia-osteoporosis syndrome. Br J Haematol. 2012 Nov;159(4):462-71.
- Neufeld EJ, Galanello R, Viprakasit V, Aydinok Y, Piga A, Harmatz P, Forni GL, Shah FT, Grace RF, Porter JB, Wood JC, Peppe J, Jones A, Rienhoff HY Jr. A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood. 2012 Apr 5;119(14):3263-8.. Epub 2012 Jan 17.
- Fung EB, Xu Y, Trachtenberg F, Odame I, Kwiatkowski JL, Neufeld EJ, Thompson AA, Boudreaux J, Quinn CT, Vichinsky EP; Thalassemia Clinical Research Network.
Inadequate dietary intake in patients with thalassemia. J Acad Nutr Diet. 2012 Jul;112(7):
- KKwiatkowski JL, Kim HY, Thompson AA, Quinn CT, Mueller BU, Odame I, Giardina PJ, Vichinsky EP, Boudreaux JM, Cohen AR, Porter JB, Coates T, Olivieri NF, Neufeld EJ; Thalassemia Clinical Research Network. Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. Blood. 2012 Mar 22;119(12):2746-53. Epub 2012 Jan 25.
- Morris CR, Kim HY, Trachtenberg F, Wood J, Quinn CT, Sweeters N, Kwiatkowski JL, Thompson AA, Giardina PJ, Boudreaux J, Olivieri NF, Porter JB, Neufeld EJ, Vichinsky EP; Thalassemia Clinical Research Network RRisk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report.
- Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report. Blood. 2011 Oct 6;118(14):3794-802. Epub 2011 Jul 19. -
Professional bodies icon plus
FRCP, FRCPath
Practice locations
NHS base
University College London Hospital NHS Foundation Trust
-
Consultant office contacts icon plus
Telephone
020 3447 7935